2015 Q2 Form 10-Q Financial Statement
#000119312516581284 Filed on May 06, 2016
Income Statement
Concept | 2015 Q2 |
---|---|
Revenue | $460.4M |
YoY Change | -4.44% |
Cost Of Revenue | $189.2M |
YoY Change | -6.25% |
Gross Profit | $271.2M |
YoY Change | -3.14% |
Gross Profit Margin | 58.9% |
Selling, General & Admin | $119.8M |
YoY Change | -9.23% |
% of Gross Profit | 44.16% |
Research & Development | $28.95M |
YoY Change | 7.32% |
% of Gross Profit | 10.68% |
Depreciation & Amortization | $11.45M |
YoY Change | -44.98% |
% of Gross Profit | 4.22% |
Operating Expenses | $148.7M |
YoY Change | -6.42% |
Operating Profit | $120.0M |
YoY Change | 1.34% |
Interest Expense | $8.975M |
YoY Change | 12.6% |
% of Operating Profit | 7.48% |
Other Income/Expense, Net | |
YoY Change | |
Pretax Income | $113.3M |
YoY Change | 1.09% |
Income Tax | $17.29M |
% Of Pretax Income | 15.25% |
Net Earnings | $96.10M |
YoY Change | -0.41% |
Net Earnings / Revenue | 20.87% |
Basic Earnings Per Share | $1.16 |
Diluted Earnings Per Share | $1.15 |
COMMON SHARES | |
Basic Shares Outstanding | 83.03M shares |
Diluted Shares Outstanding | 83.75M shares |
Balance Sheet
Concept | 2015 Q2 |
---|---|
SHORT-TERM ASSETS | |
Cash & Short-Term Investments | $2.109B |
YoY Change | 9.98% |
Cash & Equivalents | $440.8M |
Short-Term Investments | $1.668B |
Other Short-Term Assets | $115.0M |
YoY Change | 30.09% |
Inventory | $257.5M |
Prepaid Expenses | |
Receivables | $394.4M |
Other Receivables | $0.00 |
Total Short-Term Assets | $2.876B |
YoY Change | 7.29% |
LONG-TERM ASSETS | |
Property, Plant & Equipment | $316.8M |
YoY Change | -3.59% |
Goodwill | |
YoY Change | |
Intangibles | |
YoY Change | |
Long-Term Investments | |
YoY Change | |
Other Assets | $116.8M |
YoY Change | -8.18% |
Total Long-Term Assets | $996.7M |
YoY Change | -4.8% |
TOTAL ASSETS | |
Total Short-Term Assets | $2.876B |
Total Long-Term Assets | $996.7M |
Total Assets | $3.873B |
YoY Change | 3.9% |
SHORT-TERM LIABILITIES | |
YoY Change | |
Accounts Payable | $64.00M |
YoY Change | -1.69% |
Accrued Expenses | $41.80M |
YoY Change | -3.02% |
Deferred Revenue | |
YoY Change | |
Short-Term Debt | $0.00 |
YoY Change | |
Long-Term Debt Due | $175.3M |
YoY Change | -24.89% |
Total Short-Term Liabilities | $538.5M |
YoY Change | -9.43% |
LONG-TERM LIABILITIES | |
Long-Term Debt | $1.310B |
YoY Change | 12.93% |
Other Long-Term Liabilities | $140.7M |
YoY Change | 32.74% |
Total Long-Term Liabilities | $1.451B |
YoY Change | 14.59% |
TOTAL LIABILITIES | |
Total Short-Term Liabilities | $538.5M |
Total Long-Term Liabilities | $1.451B |
Total Liabilities | $2.011B |
YoY Change | 6.71% |
SHAREHOLDERS EQUITY | |
Retained Earnings | |
YoY Change | |
Common Stock | |
YoY Change | |
Preferred Stock | |
YoY Change | |
Treasury Stock (at cost) | |
YoY Change | |
Treasury Stock Shares | 74.33M shares |
Shareholders Equity | $1.862B |
YoY Change | |
Total Liabilities & Shareholders Equity | $3.873B |
YoY Change | 3.9% |
Cashflow Statement
Concept | 2015 Q2 |
---|---|
OPERATING ACTIVITIES | |
Net Income | $96.10M |
YoY Change | -0.41% |
Depreciation, Depletion And Amortization | $11.45M |
YoY Change | -44.98% |
Cash From Operating Activities | $154.6M |
YoY Change | 45.44% |
INVESTING ACTIVITIES | |
Capital Expenditures | -$21.40M |
YoY Change | -6.14% |
Acquisitions | |
YoY Change | |
Other Investing Activities | -$35.00M |
YoY Change | 12.9% |
Cash From Investing Activities | -$56.40M |
YoY Change | 4.64% |
FINANCING ACTIVITIES | |
Cash Dividend Paid | |
YoY Change | |
Common Stock Issuance & Retirement, Net | $91.03M |
YoY Change | |
Debt Paid & Issued, Net | $100.0M |
YoY Change | |
Cash From Financing Activities | -60.30M |
YoY Change | 137.4% |
NET CHANGE | |
Cash From Operating Activities | 154.6M |
Cash From Investing Activities | -56.40M |
Cash From Financing Activities | -60.30M |
Net Change In Cash | 37.90M |
YoY Change | 40.37% |
FREE CASH FLOW | |
Cash From Operating Activities | $154.6M |
Capital Expenditures | -$21.40M |
Free Cash Flow | $176.0M |
YoY Change | 36.33% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2016Q2 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-37397000 | USD |
CY2016Q2 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
|
4056000 | USD |
CY2016Q2 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-71278000 | USD |
CY2015Q2 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-60274000 | USD |
CY2015Q2 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
|
-19249000 | USD |
CY2015Q2 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
18621000 | USD |
CY2015Q2 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
120073000 | USD |
CY2015Q2 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
100000000 | USD |
CY2015Q2 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
11269000 | USD |
CY2015Q2 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
91025000 | USD |
CY2016Q2 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
15841000 | USD |
CY2016Q2 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
3740000 | USD |
CY2016Q2 | us-gaap |
Depreciation
Depreciation
|
12356000 | USD |
CY2016Q2 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
11075000 | USD |
CY2016Q2 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-38254000 | USD |
CY2016Q2 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
20488000 | USD |
CY2016Q2 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1037000 | USD |
CY2016Q2 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
3421000 | USD |
CY2016Q2 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-43632000 | USD |
CY2016Q2 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
5486000 | USD |
CY2016Q2 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
159886000 | USD |
CY2016Q2 | us-gaap |
Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
|
24652000 | USD |
CY2016Q2 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
685568000 | USD |
CY2016Q2 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-197823000 | USD |
CY2016Q2 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
110177000 | USD |
CY2016Q2 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
60000000 | USD |
CY2016Q2 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
8191000 | USD |
CY2016Q2 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
95489000 | USD |
CY2016Q2 | us-gaap |
Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
|
1619000 | USD |
CY2015Q2 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-56446000 | USD |
CY2015Q2 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
794422000 | USD |
CY2015Q2 | us-gaap |
Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
|
21410000 | USD |
CY2015Q2 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-25518000 | USD |
CY2015Q2 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
9367000 | USD |
CY2015Q2 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
154590000 | USD |
CY2015Q2 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-24961000 | USD |
CY2015Q2 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
20001000 | USD |
CY2015Q2 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1776000 | USD |
CY2015Q2 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
4891000 | USD |
CY2015Q2 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
2828000 | USD |
CY2015Q2 | us-gaap |
Depreciation
Depreciation
|
11445000 | USD |
CY2015Q2 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
11104000 | USD |
CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
422177000 | USD |
CY2016Q2 | us-gaap |
Increase Decrease In Deferred Revenue And Customer Advances And Deposits
IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits
|
45586000 | USD |
CY2015Q2 | us-gaap |
Increase Decrease In Deferred Revenue And Customer Advances And Deposits
IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits
|
42555000 | USD |
CY2015Q2 | us-gaap |
Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
|
2757000 | USD |
CY2015Q2 | us-gaap |
Payments For Proceeds From Derivative Instrument Financing Activities
PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
|
3348000 | USD |
CY2016Q2 | us-gaap |
Payments For Proceeds From Derivative Instrument Financing Activities
PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
|
1895000 | USD |
CY2016Q2 | us-gaap |
Amortization Of Deferred Charges
AmortizationOfDeferredCharges
|
11000000 | USD |
CY2015Q2 | us-gaap |
Amortization Of Deferred Charges
AmortizationOfDeferredCharges
|
11000000 | USD |
CY2016Q2 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
512397000 | USD |
CY2015Q2 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
759386000 | USD |
CY2016Q2 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style='margin-top:0pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Waters Corporation (“Waters</font><font style="font-family:Times New Roman;font-size:10pt;">®</font><font style="font-family:Times New Roman;font-size:10pt;">” or the “Company”) is</font><font style="font-family:Times New Roman;font-size:10pt;"> an analytical instrument manufacturer</font><font style="font-family:Times New Roman;font-size:10pt;"> that</font><font style="font-family:Times New Roman;font-size:10pt;"> primarily designs, manufactures, sells a</font><font style="font-family:Times New Roman;font-size:10pt;">nd services</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">high performance liquid chromatography (“HPLC”), ultra performance liquid chromatography (“UPLC</font><font style="font-family:Times New Roman;font-size:10pt;">®</font><font style="font-family:Times New Roman;font-size:10pt;">” and together with HPLC, referred to as “LC”) and mass spectrometry (“MS”) </font><font style="font-family:Times New Roman;font-size:10pt;">technology </font><font style="font-family:Times New Roman;font-size:10pt;">systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. These systems are complementary products that </font><font style="font-family:Times New Roman;font-size:10pt;">are frequently employed </font><font style="font-family:Times New Roman;font-size:10pt;">together</font><font style="font-family:Times New Roman;font-size:10pt;"> (“LC-MS”)</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">sold as integrated instrument systems using a common software platform</font><font style="font-family:Times New Roman;font-size:10pt;">. LC is a standard technique and is utilized in a broad range of industries to detect, identify, monitor and measure the chemical, physical and biological composition of materials, and to purify a full range of compounds. MS instruments are used in drug discovery and development, including clinical trial testing, the analysis of proteins in disease process</font><font style="font-family:Times New Roman;font-size:10pt;">es (known as “proteomics”), nutritional</font><font style="font-family:Times New Roman;font-size:10pt;"> safety analysis and environmental testing. LC</font><font style="font-family:Times New Roman;font-size:10pt;">-MS</font><font style="font-family:Times New Roman;font-size:10pt;"> instruments </font><font style="font-family:Times New Roman;font-size:10pt;">combine </font><font style="font-family:Times New Roman;font-size:10pt;">a liquid phase sample introduction and separation system with mass spectrometric compound identification and quantif</font><font style="font-family:Times New Roman;font-size:10pt;">ication. </font><font style="font-family:Times New Roman;font-size:10pt;">In addition, t</font><font style="font-family:Times New Roman;font-size:10pt;">he Company designs, manufactures, sells and services thermal analysis, </font><font style="font-family:Times New Roman;font-size:10pt;">rheometry</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">calorimetry</font><font style="font-family:Times New Roman;font-size:10pt;"> instruments</font><font style="font-family:Times New Roman;font-size:10pt;"> through its TA</font><font style="font-family:Times New Roman;font-size:10pt;">®</font><font style="font-family:Times New Roman;font-size:10pt;"> product line. These instruments </font><font style="font-family:Times New Roman;font-size:10pt;">are used in predicting the suitability</font><font style="font-family:Times New Roman;font-size:10pt;"> and stability</font><font style="font-family:Times New Roman;font-size:10pt;"> of fine chemicals,</font><font style="font-family:Times New Roman;font-size:10pt;"> pharmaceuticals, water,</font><font style="font-family:Times New Roman;font-size:10pt;"> polymers</font><font style="font-family:Times New Roman;font-size:10pt;">, metals</font><font style="font-family:Times New Roman;font-size:10pt;"> and viscous liquids for various industrial, consumer goods and healthcare products, as well as for </font><font style="font-family:Times New Roman;font-size:10pt;">pharmaceutical</font><font style="font-family:Times New Roman;font-size:10pt;"> research. The Company is also a developer and supplier of software-based products that interface with the Company</font><font style="font-family:Times New Roman;font-size:10pt;">'</font><font style="font-family:Times New Roman;font-size:10pt;">s instruments</font><font style="font-family:Times New Roman;font-size:10pt;">, as well as other supplier</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;">'</font><font style="font-family:Times New Roman;font-size:10pt;"> instruments,</font><font style="font-family:Times New Roman;font-size:10pt;"> and are typically purchased by customers as part of the instrument system.</font></p> | |
CY2016Q2 | us-gaap |
Fiscal Period
FiscalPeriod
|
<p style='margin-top:0pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">The Company</font><font style="font-family:Times New Roman;font-size:10pt;">'</font><font style="font-family:Times New Roman;font-size:10pt;">s interim fiscal quarter typically ends on the thirteenth Saturday of each quarter. Since the Company</font><font style="font-family:Times New Roman;font-size:10pt;">'</font><font style="font-family:Times New Roman;font-size:10pt;">s fiscal year end is </font><font style="font-family:Times New Roman;font-size:10pt;">December 31,</font><font style="font-family:Times New Roman;font-size:10pt;"> the first and fourth fiscal</font><font style="font-family:Times New Roman;font-size:10pt;"> quarters may</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">have more or less than</font><font style="font-family:Times New Roman;font-size:10pt;"> thirteen complete weeks. The Company</font><font style="font-family:Times New Roman;font-size:10pt;">'</font><font style="font-family:Times New Roman;font-size:10pt;">s </font><font style="font-family:Times New Roman;font-size:10pt;">first</font><font style="font-family:Times New Roman;font-size:10pt;"> fiscal quarters for </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2015</font><font style="font-family:Times New Roman;font-size:10pt;"> ended on </font><font style="font-family:Times New Roman;font-size:10pt;">April 2, 2016</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">April 4, 2015</font><font style="font-family:Times New Roman;font-size:10pt;">, respectively.</font></p> | |
CY2016Q2 | us-gaap |
Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
|
Cash equivalents represent highly liquid investments, with original maturities of 90 days or less, while investments with longer maturities are classified as investments. | |
CY2016Q2 | us-gaap |
Description Of Foreign Currency Exposure
DescriptionOfForeignCurrencyExposure
|
The Company is a global company that operates in over 35 countries and, as a result, the Company’s net sales, cost of sales, operating expenses and balance sheet amounts are significantly impacted by fluctuations in foreign currency exchange rates. The Company is exposed to currency price risk on foreign currency exchange rate fluctuations when it translates its non-U.S. dollar foreign subsidiaries’ financial statements into U.S. dollars, and when any of the Company’s subsidiaries purchase or sell products or services in a currency other than its own currency. | |
CY2016Q2 | us-gaap |
Description Of Foreign Currency Derivative Activities
DescriptionOfForeignCurrencyDerivativeActivities
|
The Company periodically aggregates its net worldwide balances by currency and then enters into foreign currency exchange contracts that mature within 90 days to hedge a portion of the remaining balance to minimize some of the Company’s currency price risk exposure. | |
CY2016Q2 | wat |
Derivative Notional Amount1
DerivativeNotionalAmount1
|
121000000 | USD |
CY2016Q2 | us-gaap |
Gain Loss On Foreign Currency Derivatives Recorded In Earnings Net
GainLossOnForeignCurrencyDerivativesRecordedInEarningsNet
|
-1923000 | USD |
CY2015Q2 | wat |
Realized Gain Loss On Foreign Currency Derivatives Recorded In Earnings Net
RealizedGainLossOnForeignCurrencyDerivativesRecordedInEarningsNet
|
-3348000 | USD |
CY2015Q2 | wat |
Unrealized Gain Loss On Foreign Currency Derivatives Recorded In Earnings Net
UnrealizedGainLossOnForeignCurrencyDerivativesRecordedInEarningsNet
|
342000 | USD |
CY2016Q2 | us-gaap |
Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
|
1681000 | USD |
CY2016Q2 | us-gaap |
Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
|
-2198000 | USD |
CY2015Q2 | us-gaap |
Standard Product Warranty Accrual
StandardProductWarrantyAccrual
|
12871000 | USD |
CY2015Q2 | us-gaap |
Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
|
1762000 | USD |
CY2015Q2 | us-gaap |
Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
|
-2157000 | USD |
CY2014Q4 | us-gaap |
Standard Product Warranty Accrual
StandardProductWarrantyAccrual
|
13266000 | USD |
CY2016Q2 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
2174339000 | USD |
CY2016Q2 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
1752000 | USD |
CY2016Q2 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
2175399000 | USD |
CY2016Q2 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
692000 | USD |
CY2015Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
245000 | USD |
CY2015Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
2041767000 | USD |
CY2015Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
2043996000 | USD |
CY2015Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
2474000 | USD |
CY2016Q2 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
1214006000 | USD |
CY2016Q2 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
854838000 | USD |
CY2015Q4 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
1137825000 | USD |
CY2015Q4 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
828848000 | USD |
CY2016Q2 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
2068844000 | USD |
CY2016Q2 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
92701000 | USD |
CY2016Q2 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
21811000 | USD |
CY2016Q2 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
172536000 | USD |
CY2015 | us-gaap |
Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
|
0.0124 | pure |
CY2015Q2 | us-gaap |
Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
|
727000 | shares |
CY2015Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
88625000 | USD |
CY2015Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
20901000 | USD |
CY2015Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
153889000 | USD |
CY2015Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
577728000 | USD |
CY2015 | us-gaap |
Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
|
P8Y | |
CY2016Q2 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
14220000 | USD |
CY2016Q2 | wat |
Intangible Assets Gross Foreign Currency Translation Adjustments
IntangibleAssetsGrossForeignCurrencyTranslationAdjustments
|
16000000 | USD |
CY2016Q2 | wat |
Intangible Assets Accumulated Amortization Foreign Currency Translation Adjustments
IntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationAdjustments
|
10000000 | USD |
CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
44000000 | USD |
CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
44000000 | USD |
CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
44000000 | USD |
CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
44000000 | USD |
CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
44000000 | USD |
CY2016Q2 | us-gaap |
Line Of Credit
LineOfCredit
|
499000 | USD |
CY2015Q4 | us-gaap |
Line Of Credit
LineOfCredit
|
322000 | USD |
CY2015Q4 | us-gaap |
Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
|
1668336000 | USD |
CY2016Q2 | us-gaap |
Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
|
1718800000 | USD |
CY2016Q2 | us-gaap |
Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
|
100000000 | USD |
CY2015Q4 | us-gaap |
Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
|
97000000 | USD |
CY2016Q2 | us-gaap |
Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
|
0.0148 | pure |
CY2015Q2 | wat |
Earnings Per Share Diluted Adjustment
EarningsPerShareDilutedAdjustment
|
-0.01 | |
CY2015Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
14450000 | USD |
CY2014Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
19596000 | USD |
CY2016Q2 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
13660000 | USD |
CY2015Q2 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
20529000 | USD |
CY2016Q2 | us-gaap |
Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
|
-6000000 | USD |
CY2016Q2 | wat |
Unrecognized Tax Benefits Other Changes
UnrecognizedTaxBenefitsOtherChanges
|
-790000 | USD |
CY2015Q2 | wat |
Unrecognized Tax Benefits Other Changes
UnrecognizedTaxBenefitsOtherChanges
|
933000 | USD |
CY2016Q2 | us-gaap |
Income Tax Holiday Aggregate Dollar Amount
IncomeTaxHolidayAggregateDollarAmount
|
4000000 | USD |
CY2016Q2 | us-gaap |
Income Tax Holiday Income Tax Benefits Per Share
IncomeTaxHolidayIncomeTaxBenefitsPerShare
|
0.05 | |
CY2016Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
15841000 | USD |
CY2015Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
8455000 | USD |
CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
|
7000000 | USD |
CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
|
0 | USD |
CY2015Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
|
0 | USD |
CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.015 | pure |
CY2015Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.016 | pure |
CY2016Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y | |
CY2015Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P4Y | |
CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
86000 | shares |
CY2015Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
32000 | shares |
CY2015Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
|
0.267 | pure |
CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
|
0.286 | pure |
CY2016Q2 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
122.65 | |
CY2015Q2 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
113.88 | |
CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
34.63 | |
CY2015Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
26.94 | |
CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3154000 | shares |
CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3102000 | shares |
CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
96.73 | |
CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
110.99 | |
CY2016Q2 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
81.97 | |
CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
97.60 | |
CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
54000 | shares |
CY2016Q2 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
84000 | shares |
CY2016Q2 | us-gaap |
Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
|
699000 | shares |
CY2016Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1200000 | shares |
CY2015Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
600000 | shares |
CY2016Q2 | wat |
Earnings Per Share Diluted Adjustment
EarningsPerShareDilutedAdjustment
|
-0.01 | |
CY2016Q2 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
2 | pure |
CY2016Q2 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | pure |